Kyverna Therapeutics, Inc. Common Stock

KYTX XNAS • BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

450M

Short interest (Jul 15)

12.9%

Net Short (Jul 27 ): 0.0%

Borrow Fee

0.41%

↓ 15.1%

Available Shares

↑ 55.4%

Price Chart

Company Overview

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Company Info

Exchange: NASDAQ

Industry: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

CIK: 0001994702

Asset Type: CS

Market Data

Market Cap: $450,492,520

Employees: 129

Status: Active

Short Interest

Current Borrow Fee 0.41%

Range: 0.41% - 0.41%

Available Shares 2M

Range: 550K - 2M

Recent Changes

Fee Change: ↓ 2.2%

Available Change: ↓ 2.4%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime